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Abstract
Introduction. Medtronic released a subset of dual chamber pacemakers that are suspected of a software error that can 
result in a lack of pacing. The Food and Drug Administration has deemed a class I recall.
Material and methods. Medtronic advise reprogramming for patients with susceptible mode to non-susceptible pacing 
modes that are: DVI, DVIR, DOO(R), VVI, VVIR, VOO(R), VVT, AAI, AAIR, AOO(R), AAT, OVO.
Results. 48 patients received an atrioventricular recalled device. Initially the DDD/DDDR mode was programmed in 
44 patients and VVI/VVIR mode in the other four patients. The atrial and ventricular lead parameters such as pacing 
threshold, sensing threshold and impedance were within normal ranges. Pacemaker dependency in atria concerned 
16/48 (33.33%) patients and in ventricles 13/48 (27.1%) patients. Three patients complained of fatigue, dizziness 
and near syncope. In 24 patients, devices were reprogrammed: in 17 (35.41%) patients to the DVIR mode and in seven 
(14.58%) patients to the VVI(R) mode. Two patients chose to be reprogrammed to the DDDR mode because of intole-
rance to non-susceptible pacing modes.
Conclusions. Only three patients experienced symptoms that may be associated with pacemaker dysfunction; in 24/ 
/48 patients we programmed safety mode DVI(R) or VVI(R). The pacemaker dependency concerned almost 33.33% 
of patients.
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Introduction
Between 6 March 2017 and 7 January 2019, Medtronic 
released a subset of dual chamber pacemakers under the 
brand names Adapta, Versa, Sensia, Relia, Attesta, Sphera, 
and Vitatron A, E, G, and Q series. These are suspected 
of a software error that can result in a lack of pacing. 
There are 13,440 recalled devices in the United States 
of America, 20,000 in Poland, and a total of 156,957 
worldwide [1, 2]. The Food and Drug Administration (FDA) 
has deemed a class I recall i.e. the most serious one [3]. 
No deaths have been reported. Medtronic estimates that 
a device in a susceptible pacing mode has a 2.8% chance 
per month of experiencing a pacing pause of 1.5 seconds 
or longer. The lower risk concerns patients with preserved 
own rhythm, since ventricular sensed beats restore full 
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device functionality. The estimated per patient mortality 
risk of 0.021% associated with device failure is comparable 
with the mortality risk of 0.027% associated with device 
replacement. Medtronic recommends programming to 
a non-susceptible pacing mode until the software update 
has been installed. The non-susceptible pacing modes 
are: DVI, DVIR, DOO(R), VVI, VVIR, VOO(R), VVT, AAI, AAIR, 
AOO(R), AAT, OVO. The company is developing a software 
update to fix this problem [1, 2]. The aim of this study was to 
characterise the subset of patients with implanted recalled 
devices produced by Medtronic.
Material and methods
48 patients (25 male, 23 female) underwent pacemaker 
control due to Medtronic device recall who were implan-
ted between 10 March 2017 and 7 January 2019 in the 
Outpatient Clinic for Cardiovascular Implantable Electronic 
Devices. The mean patient age was 75.85 years, with 
a range from 41 to 95. The main reason for pacemaker 
implantation was sick sinus syndrome (Table 1). The most 
frequent observations were hypertension (39/48; 81.25%), 
coronary artery disease (23/48, 47.91%) and chronic renal 
failure (32/48; 66.67 %) (Table 2).
Reprogramming
Medtronic advised reprogramming for patients with su-
sceptible mode and persistent atrial fibrillation into VVI(R) 
mode, in patients who had no underlying ventricular escape 
rhythm or who were at risk for a symptomatic pause until 
a ventricular escape beat occurs. Programming to a non-
-susceptible mode was recommended and should be 
followed by routine clinical monitoring. In patients who 
cannot tolerate a non-susceptible mode, clinical monitoring 
in susceptible mode can continue or it may be sensible to 
consider device replacement. The patients remaining in 
susceptible mode were told to seek immediate medical 
advice if symptoms appeared [1].
The advice of the Working Group set up by the 
Polish National Consultants in Cardiology and The 
Heart Rhythm Section of the Polish Cardiac Society 
was to coordinate actions, identify patients, contact 
patients, perform at least two control visits to patients 
reprogrammed to non-susceptible mode, and perform 
device exchange in patients who could not tolerate non-
-susceptible mode [2].
Definition
Pacemaker dependency is defined as rhythm < 30/min or 
symptoms present and rhythm between 30 and 40/min.
Results
48 patients received an atrioventricular recalled device. 
In 32 patients, this was the first implantation, while in 16 
patients it was a device exchange due to the end of battery 
life. Initially the DDD/DDDR mode was programmed in 44 
patients and the VVI/VVIR mode in the other four patients. 
The atrial and ventricular lead parameters such as pacing 
threshold, sensing threshold and impedance are set out 
in Table 3. The mean atrial pacing was 54.3%, range 0 to 
99.8%, and the mean ventricular pacing was 95%, range 
0.1 to 100%. Pacemaker dependency in atria concerned 
16/48 (33.33%) patients and in ventricles 13/48 (27.1%) 
patients. Three patients complained of fatigue, dizziness 
and near syncope. In 24 patients, devices were repro-
grammed: in 17 (35.41%) patients to the DVIR mode and 
in seven (14.58%) patients to VVI(R). In two patients DVIR 
mode was not tolerated, and both these patients decided 
to be reprogrammed to the DDDR mode.
We identified AHR in 22 patients (11 in patients with 
a previous diagnosis of atrial fibrillation) and VHR in 10 pa-
tients. There were 2,374 AHR episodes, and the mean 
number of AHR was 55.21, range from 1,235 to 1. While 
there were 93 VHR episodes, the mean number of VHR 
was 2.02, range from 62 to 1.
The control visit included interview, examination, device 
control and reprogramming, presentation of informed con-
sent, and signing the consent — duration time 30 minutes. 
Table 1. Indications for pacemaker implantation
Indication for pacemaker implantation Number of  
patients [%]
Sick sinus syndrome 23 (47.91)
Tachycardia–bradycardia syndrome 2 (4.17)
Advanced atrioventricular block (2:1) 14 (29.17)
Sick sinus syndrome and advanced atrio-
ventricular block (2:1)
2 (4.17)
Atrioventricular block and sequential 
RBBB and LBBB
1 (2.08)
RBBB — right bundle branch block; LBBB — left bundle branch block
Table 2. Patient characteristics
Parameter Number [%] of patients
Coronary artery disease 23/48 (47.91%)
Myocardial infarction 7/48 (14.58%)
Hypertension 39/48 (81.25%)
Atrial fibrillation 18/48 (37.5%)
Ischaemic stroke 5/48 (10.42%)
Diabetes mellitus 17/48 (35.42%)
Chronic renal failure 32/48 (66.67%)
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Although patients were nervous and uncertain nobody 
asked for device exchange.
Discussion
We present the initial experience of our Centre with recalled 
Medtronic devices affected by a circuit error that may lead 
them to withhold ventricular pacing. Our main finding was 
that only three patients experienced symptoms that may 
be associated with pacemaker dysfunction, while in 24/48 
patients we programmed safety mode DVI(R) or VVI(R). The 
pacemaker dependency concerned almost 30% of patients.
In the literature, pacemaker dependency among 
3,638 patients was diagnosed in 2.1% of all patients and 
more frequently was observed in patients with atrioventri-
cular block compared to patients with sick sinus syndrome 
or atrial fibrillation [4]. In our population, advanced atrio-
ventricular block was diagnosed in 16 patients (33.34%), 
while sick sinus syndrome and tachycardia–bradycardia 
syndrome concerned 25 patients (52.08%). Patients with 
cardiovascular electronic devices experience depressive 
disorders, and the number of patients affected with such 
a disorder may increase over time [5]. Unfortunately, 
stressful information such as the possible dysfunction of 
a CIED (device recall) may worsen existing disorders.
We designed a control visit that would last for 30 min. 
All this time was exploited as usually patients needed to 
be informed twice for better understanding and to calm 
nerves. 30 min for each of 48 patients means an additio-
nal 1,440 min for the Outpatient Clinic for Cardiovascular 
Implantable Electronic Devices, something that markedly 
increased the workload. As patients with recalled devices 
need to be carefully followed up, we scheduled control 
visits every two months.
This present dual-chamber pacemaker recall comes 
after last year’s Medtronic resynchronisation therapy and 
implantable cardioverter defibrillator class 1 recall which 
was due to a manufacturing error preventing electrical 
shock delivery that was announced on 22 January 2018 [6].
When Maisel et al. [7] analysed pacemaker and implan-
table cardioverter-defibrillator generator advisory rates in 
the United States, they found that recalls and safety alerts 
occur frequently, affect many patients, and appear to be 
increasing both in number and rate.
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Mean pacing threshold [V/0.4 ms] 0.578 0.62
Impedance [ohm] 709.13 575.3
Mean maximal sensing threshold [mV] 3.3 21.24
Pacemaker dependency 13/48 16/48
Mean percentage of pacing [%] 54.3 95
Streszczenie
Wstęp. Firma Medtronic wypuściła na rynek grupę przedsionkowo-komorowych stymulatorów podejrzanych o błąd 
oprogramowania, który może prowadzić do wstrzymania stymulacji. Agencja ds. Żywności i Leków objęła powyższe 
urządzenia alertem klasy pierwszej.
Materiały i metody. Firma Medtronic zaleca zmianę programu u chorych stymulowanych w trybie podatnym na wystąpienie 
błędu na tryb niepodatny, czyli: DVI, DVIR, DOO(R), VVI, VVIR, VOO(R), VVT, AAI, AAIR, AOO(R), AAT, OVO.
Wyniki. Przedsionkowo-komorowy stymulator objęty obecnie alertem wszczepiono 48 chorym. U 44 pacjentów począt-
kowo występował tryb DDD/DDDR, natomiast u 4 pacjentów — VVI/VVIR. Parametry elektrod, takie jak próg stymulacji, 
amplituda sygnału czy oporność, pozostawały w granicach normy. Zależność od stymulatora w przedsionkach dotyczyła 
16 spośród 48 (33,33%) pacjentów, natomiast w komorach — 13 spośród 48 (27,1%) chorych. U 3 osób wystąpiły 
zmęczenie, zawroty głowy, prawie omdlenie. U 24 chorych stymulatory przeprogramowano w tryb bezpieczny — u 17 
(35,41%) pacjentów w tryb DVIR, a 7 (14,58%) chorych w tryb VVI(R). Dwóch chorych zdecydowało o powrocie do trybu 
DDDR z powodu nietolerancji trybów niepodatnych na wystąpienie błędu.
Wnioski. Trzech pacjentów doświadczyło objawów, które mogą się wiązać z dysfunkcją stymulatora, u 24 z 48 chorych 
zaprogramowano tryb bezpieczny [DVI(R) lub VVI(R)]. Stymulatorozależność dotyczyła 33,3% chorych.
Słowa kluczowe: stymulator dwujamowy, alert bezpieczeństwa, alert Medtronic
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